Abstract:Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance. Teleologically, myeloid cells, including macrophages, dendritic cells, monocytes, and neutrophils, initiate a response to invading pathogens and tissue repair after pathogen clearance is successfully accomplished. However, in the tumor microenvironment (TME), these innate cells are hijacked by the tumor cells and are imprinted to furthering tumor propagation and dissemination. Major advancements have been made in the field, especially related to the heterogeneity of myeloid cells and their function in the TME at the single cell level, a topic that has been highlighted by several recent international meetings including the 2021 China Cancer Immunotherapy workshop in Beijing. Here, we provide an up-to-date summary of the mechanisms by which major myeloid cells in the TME facilitate immunosuppression, enable tumor growth, foster tumor plasticity, and confer therapeutic resistance. We discuss ongoing strategies targeting the myeloid compartment in the preclinical and clinical settings which include: (1) altering myeloid cell composition within the TME; (2) functional blockade of immune-suppressive myeloid cells; (3) reprogramming myeloid cells to acquire pro-inflammatory properties; (4) modulating myeloid cells via cytokines; (5) myeloid cell therapies; and (6) emerging targets such as Siglec-15, TREM2, MARCO, LILRB2, and CLEVER-1. There is a significant promise that myeloid cell-based immunotherapy will help advance immuno-oncology in years to come.

An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges

Investigating T Cell Immunity in Cancer: Achievements and Prospects

Advances in Engineering Cells for Cancer Immunotherapy

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

Implications for Cancer Immunology and Therapy

The Interplay between T Cells and Cancer: The Basis of Immunotherapy

Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy

Cancer immunotherapies: advances and bottlenecks.

Immune Cell Recruitment and Cell-Based System for Cancer Therapy

Immune responses and immunotherapeutic approaches in the treatment against cancer

The New Progress in Cancer Immunotherapy

Dendritic cell subsets and implications for cancer immunotherapy

Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets

Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy

The complex role of regulatory cells in breast cancer: implication for immunopathogenesis and immunotherapy

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness